Azitra announced the completion of Cohort 1 and clearance for Cohort 2 of a clinical trial evaluating drug candidate ATR04-484 as a treatment for EGFR inhibitor-induced skin rash, following a safety review. The advancement marks a significant milestone for the company's live biotherapeutic program addressing a common side effect in oncology.